Albizia for Anxiety Relief

Research suggests that Albizia julibrissin and related species demonstrate consistent anxiolytic activity across a body of preclinical animal studies, with identified mechanisms including modulation of serotonergic pathways (particularly 5-HT1A receptors), GABAergic and benzodiazepine receptor systems, HPA axis regulation, and serotonin transporter inhibition. Studies indicate that specific isolated constituents — including saponins, julibroside C1, and lignan glycosides — appear to account for much of this activity, and multiple systematic and narrative reviews published between 2013 and 2025 have consistently characterized Albizia as a pharmacologically promising anxiolytic candidate aligned with its traditional use. However, the available evidence is entirely preclinical in nature, drawn from animal models such as the elevated plus maze rather than human clinical trials, which represents a significant limitation in drawing conclusions about efficacy or safety in people. The collective direction of the research is supportive, but reviewers have generally noted that well-designed human studies are needed before stronger conclusions can be drawn.